Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2008 Dec;4(6):1221-7.
doi: 10.2147/tcrm.s4314.

Targeting colorectal cancer with anti-epidermal growth factor receptor antibodies: focus on panitumumab

Daanish Hoda  1 , George R Simon, Christopher R Garrett
Affiliations

Targeting colorectal cancer with anti-epidermal growth factor receptor antibodies: focus on panitumumab

Daanish Hoda et al. Ther Clin Risk Manag. 2008 Dec.

Abstract

Panitumumab is a fully humanized monoclonal antibody with a high degree of affinity for the extracellular domain of the epidermal growth factor receptor. Phase II clinical evaluation of this drug, when administered as a single agent, in patients with metastatic colorectal cancer refractory to chemotherapy, demonstrated a modest objective radiographic response rate with acceptable toxicity; the most frequently observed side effect is rash. A randomized phase III study in subjects with chemotherapy-refractory metastatic colorectal cancer documented a progression-free survival advantage in subjects treated with panitumumab plus best supportive care versus best supportive care alone; a difference in survival was not observed, likely due to the high cross over rate. Primary tumor KRAS mutation analysis performed in this study indicated that the benefit was confined to those patients whose tumors did not contain a KRAS mutation. Further studies with panitumumab will be required to develop biomarkers of response and to determine if panitumumab has a role in combination with cytotoxic chemotherapy. This article summarizes the current state-of-the-science knowledge on panitumumab therapy in the treatment of advanced colorectal cancer.

Keywords: colorectal cancer; epidermal growth factor receptor; monoclonal antibody; panitumumab.

PubMed Disclaimer

References

    1. Amado RG, Wolf M, Peeters M, et al. Wild-type KRAS is required for panitumumab efficacy in patients with colorectal cancer. J Clin Oncol. 2008;26:1626–34. - PubMed
    1. Barault L, Veyrie N, Jooste V, et al. Mutations in the RAS-MAPK, PI(3)K (phosphatidylinositol-3-OH kinase) signaling network correlate with poor survival in a population-based series of colon cancers. Int J Cancer. 2008;122:2255–9. - PubMed
    1. Bokemeyer C, Bondarenko I, Hartmann JT, et al. KRAS status and efficacy of first-line treatment of patients with metastatic colorectal cancer with FOLFOX with or without cetuximab: The OPUS experience. Proc Am Soc Clin Oncol. 2008;26 (abstract 4000)
    1. Chung KY, Shia J, Kemeny N, et al. Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J Clin Oncol. 2005;23:1803–10. - PubMed
    1. Cocker KJ, Staros JV, Guyer CA, et al. A kinase-negative epidermal growth factorreceptor that retains the capcity to stimulate DNA synthesis. Proc Natl Acad Sci U S A. 1994;91:6967–71. - PMC - PubMed